Notch expression has been shown to be aberrant in brain arteriovenous malformations (AVM), and targeting Notch has been suggested as an approach to their treatment. It is unclear whether extracranial vascular malformations follow the same patterning and Notch pathway defects. In this study, we examined human extracranial venous (VM) (n = 3), lymphatic (LM) (n = 10), and AV (n = 6) malformations, as well as sporadic brain AVMs (n = 3). In addition to showing that extracranial AVMs demonstrate interrupted elastin and that AVMs and LMs demonstrate abnormal α-smooth muscle actin just as brain AVMS do, our results demonstrate that NOTCH1, 2, 3 and 4 proteins are overexpressed to varying degrees in both the endothelial and mural lining of the malformed vessels in all types of malformations. We further show that two gamma secretase inhibitors (GSIs), DAPT (GSI-IX) and RO4929097, cause dose-dependent inhibition of Notch target gene expression (Hey1) and rate of migration of monolayer cultures of lymphatic endothelial cells (hLECs) and blood endothelial cells (HUVEC). GSIs also inhibit HUVEC network formation. hLECs are more sensitive to GSIs compared to HUVEC. GSIs have been found to be safe in clinical trials in patients with Alzheimer's disease or cancer. Our results provide further rationale to support testing of Notch inhibitors in patients with extracranial vascular malformations.
Vascular malformations are developmental abnormalities of venous, arterial, capillary or lymphatic vessels which grow with an individual. These can be purely of one type of vessel (e.g., venous [VM] or lymphatic malformations [LM]) or can involve more than one type (e.g., venolymphatic malformations [VLM] or arteriovenous malformations [AVM] 1 . Morbidities are significant such as pain, infection, pulmonary emboli, bleeding, cosmetic concerns, psychosocial issues, and even death. Current treatments include supportive care with compression garments, and interventions such as sclerotherapy, embolization, and surgical debulking or resection. There has been a growing interest in medical management of vascular malformations 2 . The mammalian target of rapamycin (mTOR) inhibitor, rapamycin (Sirolimus), is the most commonly used drug, but does not result in complete resolution of lesions 3 . While generally well-tolerated, its results often are not permanent, and life-long treatment may be needed. Thus, there is a need for other medications.
Notch proteins (Notch 1-4) are a family of receptors that are important in cell differentiation in virtually all tissues. The Notch pathway governs arteriovenous specification leading to distinction of arteries from veins 4 , and paradoxically both loss-or gain-of-function of Notch receptors have been linked to vascular malformations 4 . Ectopic Notch1 5 or Notch4 6-9 activation in endothelial cells results in AVMs. Importantly, activation of Notch4 in the endothelium of adult mice results in AVMs in organs, including liver, skin, uterus and brain 7 , and AVM formation was reversible upon loss of Notch4 transgene expression. Likewise, it has been shown that NOTCH1 signaling is activated in human brain AVMs 9, 10 . Knockdown of Notch1 in endothelial cells (ECs) has been found SCieNTifiC RePORTS | (2018) 8:17987 | DOI:10.1038/s41598-018-36628-1 to decrease LEC proliferation and migration 11, 12 . Different results may reflect tissue-, species-, and developmental stage-specific differences in the role of Notch signaling, but are all consistent with a role for Notch in aberrant angiogenesis. Several investigators have suggested targeting Notch as an approach to treating AVMs.
In mammals, the Notch signaling pathway is triggered by binding of Notch proteins to any of four activating ligands (Delta-like [Dll1, Dll4], Jagged [Jag1, Jag2]) which ultimately trigger transmembrane cleavage by a gamma-secretase complex, resulting in release of the Notch intracellular domain (NICD), which activates transcription of downstream target genes such as EphrinB2 13 . This is of particular interest because a number of gamma secretase inhibitors (GSI) have undergone phase I and II clinical trials in adults with Alzheimer's disease 14, 15 and in children and adults with cancer and related disorders [16] [17] [18] . That these drugs have known dosing and acceptable safety profiles makes them good candidates for drug repurposing for patients with other disorders such as vascular malformations.
In this study, we show that extracranial vascular malformations, like brain AVMs, are characterized by diminished and incomplete smooth muscle actin (αSMA) in the vascular smooth muscle cells (VSMC) of AVM, and diminished elastin coverage in the internal elastin lamina (IEL) of AVMs. NOTCH1-4 proteins are variably expressed in a range of these extracranial vascular malformations involving lymphatic, venous and arterial vessels. Moreover, two GSIs-DAPT and RO4929097-caused dose-dependent inhibition of Notch target gene expression (Hey1) and angiogenesis of both lymphatic and blood endothelial cells in vitro. These results provide additional rationale to support clinical trials of GSIs in patients with vascular malformations.
Results
Extracranial vascular malformations have discontinuous elastin fibers in their internal elastic lamina. Human brain AVMs have disrupted elastin fibers, which compromise the structural integrity of the vessel and mediate arteriovenous malformations [19] [20] [21] . While brain elastin content has been well characterized, the elastin in extracranial vascular malformation has not been studied. Therefore, we evaluated tissue samples from human extracranial AVM for elastin fibers in the IEL. Compared to control vessels ( Fig. 1A,B ), both brain ( Fig. 1C ,D) and extra-cranial AVMs ( Active NOTCH1 is expressed in abnormal human extracranial vascular channels. Normal arteries have a uniform layer of αSMA-positive mural cells around them, and in contrast, normal lymphatic capillaries have a single endothelial layer with no mural cell coverage. However, arteries involved in AVMs are characterized by incomplete αSMA coverage and malformed lymphatic vessels gain mural cell coverage around them 22 (Fig. 2 ). Due to the role of Notch signaling in normal and pathological vascular development and arterial venous specification, we determined the expression of active NOTCH1 intracellular domain (NOTCH1-ICD) in abnormal vascular channels (VC). Compared to minimal expression in normal (N) vessels with complete αSMA (Fig. 2C ), NOTCH1-ICD was clearly seen in all the abnormal VC ( Fig. 2A,B ,D-F) within the same sections. There was no NOTCH1-ICD expression overlapping with αSMA staining indicating that NOTCH1 is primarily activated in the endothelium of malformed vessels. An additional 8 tissues from a broad spectrum of LM subtypes were stained with an antibody against the extracellular domain of NOTCH1, and the lymphatic endothelial protein, PODOPLANIN (Supplemental Table 1 ). NOTCH1 expression was observed in the endothelium of 6 of these LM samples, but not in normal lymphatic vessels.
NOTCH2 and 3 are expressed in endothelial and mural cells surrounding vascular malformations.
Studies have shown that NOTCH2 is minimally expressed, while NOTCH3 is overexpressed in human brain vascular malformations and a combined loss of one allele of Notch1 with Notch3 deletion results in CADASIL (a genetically mediated arteriopathy primarily of cerebral arteries and arterioles) and AVMs in mice 21, 23 . Therefore, we examined NOTCH2 and NOTCH3 expression in extracranial LM and VM. Our results show NOTCH2 and NOTCH3 clearly are expressed in endothelial and mural cells lining both VMs and LMs, and appear to be increased compared to normal vessels (N) within the same field ( Fig. 3A-D ). NOTCH2 was expressed in cells outside of the vasculature in venous malformations and it was distinctly expressed mainly in vascular channels of LMs (Fig. 3A ,C). NOTCH3 staining was obvious in both LM and VM ( Fig. 3B,D) . Our results suggest that unlike in brain AVMs, NOTCH2 and NOTCH3 are expressed in extracranial lymphatic and venous malformations, and in the endothelial and to some extent even mural cell layer surrounding the malformations.
NOTCH4 shows variable expression in malformed vessels of venous, lymphatic and arteriovenous origin.
Staining with an antibody against NOTCH4-intracellular domain (NOTCH4-ICD) demonstrated varied expression across different types of malformations. Lymphatic malformation sections showed strong NOTCH4-ICD expression in CCD31+ endothelial cells lining the abnormal vascular channels consistent with active NOTCH4-ICD signaling (Fig. 4A,D) . NOTCH4-ICD expression in AVM sections was minimal with occasional high expression in a few endothelial cells ( Fig. 4B ,E). Tissue from VM showed weak and interrupted NOTCH4-ICD expression in CD31 weak vessels and was absent from CD31+ abnormal vascular channels ( Fig. 4C,F) . Collectively, these data suggest a link between the misexpression of Notch family members and NOTCH1 and NOTCH4 activation in human extracranial vascular malformations of all types.
DAPT and RO4929097downregulate Hey1 expression in blood and lymphatic endothelial cells without altering human cell viability. First, we confirmed that the GSIs in concentrations used in this study are successful in inhibiting the Notch signaling pathway in human blood (HUVECs) and lymphatic SCieNTifiC RePORTS | (2018) 8:17987 | DOI:10.1038/s41598-018-36628-1 endothelial cells (hLECs) without altering their viability. Cell viability was not significantly different compared to untreated controls at concentrations less than 20 μM on either cell type. 20 μM of DAPT and RO4929097 reduced hLEC viability by almost 30% without significant changes observed at lower concentrations ( Fig. 5A ). Neither drug altered HUVEC cell viability at any of the concentrations tested (Fig. 5B ). The expression of the NOTCH target gene Hey1 was significantly downregulated in both cell lines. DAPT downregulated Hey1 expression in HUVECs beginning at 4 μM, while 2 μM of RO4929097 was sufficient to downregulate Hey1 (Fig. 5C ). hLECs appeared more sensitive to GSIs, with both drugs causing inhibition at concentrations as low as 2 μM (Fig. 5D ).
γ-secretase inhibitors can effectively inhibit angiogenesis of both human blood and lymphatic cultured endothelial cells.
While the use of DAPT in the inhibition of migration and proliferation of blood endothelial cells has been well characterized [16] [17] [18] [19] , to our knowledge there are no studies for the use of DAPT or RO4929097 on lymphatic endothelial cells. Therefore, we investigated the effectiveness of both these GSIs on the rate of migration of monolayer cultures of hLEC and HUVEC cells ( Fig. 6A,B ). 8 μM of DAPT reduced hLEC migration to about 50% and HUVEC migration to about 35% while RO4929097 was more effective at 6 μM in both cell types ( Fig. 6C,D) . RO4929097 reduced migration in hLECs by greater than 50% at lower concentrations compared to HUVECs.
We determined the effect of GSIs on network formation of cultured human endothelial cells. Evaluation of tube formation by HUVEC in a matrigel matrix after treatment with increasing doses of DAPT and RO4929097showed that network formation was dramatically reduced even with the lowest concentration (2 μM) of the GSIs (Fig. 7A,B ). The number of branch points seen per field, an operational read-out of network formation assays, was significantly reduced with all concentrations of DAPT and RO4929097, with the latter being more potent in inhibiting network formation (Fig. 7C,D) . Taken together, our results demonstrate that, HUVECs and hLECs are susceptible to both GSIs, and that lymphatic endothelial cells are more susceptible to GSIs compared to HUVECs.
Discussion
In this study, we examined a wide range of human extracranial vascular malformations involving lymphatic, venous and arterial vessels and demonstrate that Notch proteins are expressed in each type. Although our results are qualitative, activated NOTCH1-ICD is more apparent in endothelial cells lining extracranial LM, VM and AVM compared to normal vessels within the same tissue. Full length NOTCH1 expression is observed in the endothelium of a majority of the LMs independent of whether the lesion was a focal (cystic LM) or multi-focal (generalized lymphatic anomaly/Gorham Stout). The broader expression of full length NOTCH1 than NOTCH1-ICD in the LM endothelium is consistent with the mechanism of NOTCH signaling, where Notch active cells are surrounded by ligand-expressing Notch inactive cells. NOTCH2 and NOTCH3 were expressed in endothelial and mural cells lining both VMs and LMs, and appeared to be increased compared to what we observed in normal vessels. NOTCH4-ICD was present in LM, but was sparsely expressed in both brain and extracranial AVM and VM. Our results suggest that Notch signaling plays a key role in human extracranial lymphatic, venous, and arteriovenous malformations and adds to the previously focused information on NOTCH overexpression in brain AVMs. We also found that, similar to those in the brain, extracranial AVMs showed interrupted αSMA and elastin layer surrounding malformed vessels.
The GSIs, DAPT and RO4929097, were effective in inhibiting angiogenesis in Notch-expressing HUVECs. RO4929097, which has been used in human clinical trials 17 , was more potent on a molar basis than DAPT, commonly used in vitro. Furthermore, hLECs were more susceptible to Notch inhibition than HUVECs. Our results are consistent with previous findings of GSI inhibition of HUVEC migration and tube formation [24] [25] [26] and add to the information with comparative analysis between two GSIs across two different endothelial cells lines. Although GSIs are known to be direct inhibitors of Notch, it also is possible that these drugs have effects downstream of Notch, e.g., on EphrinB2, which also is gamma secretase-processed when activated. Nonetheless, taken together our results present a strong impetus for targeting the Notch signaling pathway in the management and treatment of extracranial lymphatic, venous and arteriovenous malformations with GSIs. Combined loss of one allele of Notch1 and global deletion of Notch3 has been linked with retinal AVMs in mice 23 . Notch2, while not described to be expressed in normal peripheral vascular cells, has a role in renal and eye capillary development 27 . Notch-mediated communication between vascular endothelial cells and smooth muscle cells is critical during normal vascular development. Notch signaling is also important to the pathogenesis of vascular disease, and lies both upstream and downstream of critical vascular and lymphatic growth signals such as VEGF, EphB4/ ephrinB2 and adrenomedullin/CLR signaling [28] [29] [30] . Data on the role of Notch in human vasculature are limited, but patients with CADASIL are known to have missense mutations in Notch3 or Jag1 31 . Patients with Alagille syndrome, a pleiotropic developmental disorder involving multiple organs, have demonstrated mutations in the Notch ligand Jag1 32 . Our results support and extend several studies which have identified NOTCH1, 3 and 4 Fig. A and D) , arteriovenous malformation (AVM, Fig. B  and E) , and venous malformation (VM, Fig. C and F) . n = 2 each group. Scale bar, 100 μm. Arrows point to endothelial lining of vessels showing the presence or absence of NOTCH4-ICD. Our observations are of particular interest because several GSIs already have been through clinical trials, both in children and adults. Tolerated doses and schedules for oral administration have been well defined, particularly in older patients. Although lack of efficacy in Alzheimer's disease, the initial target population, led to shut-down of development of this class of drugs by the pharmaceutical industry, some efficacy was suggested in leukemias, solid tumors and in benign but locally aggressive desmoid tumors [14] [15] [16] [17] [18] . The maximum concentrations observed in pharmacokinetic studies of RO4929097 in patients with cancer were in the range of concentrations which we studied 34 . Renewed interest in making drug available for one or more of these indications or for other rare disorders seems likely in the near future. We studied only one of 5 GSIs which have been used in humans. Preclinical testing of the other four drugs of this class will be of interest. Additional preclinical studies will be needed to detail the signaling pathways involved in development and progression of vascular malformations. However, we suggest that these can proceed concurrent with pilot phase II clinical trials of Notch inhibitors in patients with these disorders.
Materials and Methods
Patient samples and IRB approval. We confirm that all experimental protocols were carried out in accordance with relevant guidelines and regulations. All experimental protocols were approved by the following IRB committee: A database (approved by the University of North Carolina [UNC] School of Medicine's Institutional Review Board [IRB]) of all patients with vascular anomalies (ICD9 747.64, 74; 7.60, 759.9, 228) seen at UNC January 2000-January 2016 by members of our multi-disciplinary Vascular Anomalies Clinic was compiled (JB, KP). Entries were reviewed for diagnostic accuracy, patient demographics, the availability of relevant archived biopsies, location of the anomaly, and treatment prior to biopsy. For human studies at UNC, LM, VM, and AVM tissue samples were collected from archived surgical specimens and samples were de-identified. A waiver of consent and waiver of HIPPA authorization were approved by the UNC IRB (IRB 15-1423). For human studies at Columbia, de-identified LM tissues were collected from discarded surgical specimens. As protected health information (PHI) was neither stored nor disclosed to the researchers, tissues were collected under exemption by Columbia University IRB (AAAA7338) and thus, there was no verbal or written consent required.
After cultures were trypsinized, washed, and 10 μL of cell sample was mixed with an equal amount of 0.4% trypan blue stain and loaded onto the counting chamber.
Scratch migration assay. Migration assay was performed as per Liang et al. 35 . HUVECs and hLECs were grown to confluence in 24 well dishes, and then scratched with a 200 ul pipette tip. After scratching, the wells were rinsed with 1XPBS to remove non-adherent cells and then treated with control DMSO or increasing concentrations [2, 4, 6, 8, 10, 20 μM] of DAPT or RO4929097. Four fields per well were imaged at T = 0 hrs and at T = 24 hrs post-scratch or T = 72 hrs for HUVECs and hLECs respectively using an Olympus IX-81 inverted microscope equipped with a QImaging Retiga 4000 R camera at 4X magnification. The percent change in migration was calculated by measuring the open area of the scratch at the above mentioned time-points (ImageJ). Results shown are representative of four independent experiments with HUVECs and three for hLECs.
Tube formation assay. This assay was performed based on the protocol by Arnaoutova and Kleinman 36 . Briefly, HUVEC cells were serum-starved after reaching 70-80% confluence, trypsinized, washed and plated at similar concentrations in a Growth Factor Reduced Matrigel Matrix (BD Biosciences 356230) coated 96-well plate and submerged in growth medium containing either control DMSO or increasing concentrations (2, 4, 6, 8, 10, 20 uM) of DAPT or RO4929097.
